| Source: |
| Type: |
| Also called CCND1 Gatekeeper of Cell-Cycle Commitment The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression. Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer. Cyclin D1 is often found to be overexpressed in various cancers. Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression. Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer. In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response. |
| 2776- | Bos, | Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities |
| - | Review, | Var, | NA |
| 2775- | Bos, | The journey of boswellic acids from synthesis to pharmacological activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 2767- | Bos, | The potential role of boswellic acids in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2773- | Bos, | Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer |
| - | Review, | Var, | NA |
| 1169- | Bos, | Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers |
| - | in-vivo, | CRC, | NA |
| 1427- | Bos, | Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 1422- | Bos, | Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 1426- | Bos, | CUR, | Chemo, | Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer |
| - | in-vivo, | CRC, | NA | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vitro, | RCC, | SW-620 | - | in-vitro, | RCC, | HT-29 | - | in-vitro, | CRC, | Caco-2 |
| - | in-vitro, | Pca, | DU145 |
| 5732- | Buty, | GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon |
| - | Study, | CRC, | NA |
| 1230- | CA, | Caff, | Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | Human, | NA, | NA |
| 1652- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | Var, | NA |
| - | in-vitro, | Cerv, | SiHa |
| 5746- | CA, | Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 5877- | CA, | Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells |
| - | in-vitro, | CRC, | HCT116 |
| 5866- | CA, | Carnosic acid inhibits STAT3 signaling and induces apoptosis through generation of ROS in human colon cancer HCT116 cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | HT29 |
| 5199- | CAP, | Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation |
| - | vitro+vivo, | AML, | NA |
| 1260- | CAP, | Capsaicin inhibits in vitro and in vivo angiogenesis |
| - | vitro+vivo, | NA, | NA |
| 1517- | CAP, | Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1) |
| - | in-vitro, | Bladder, | TSGH8301 | - | in-vitro, | CRC, | T24/HTB-9 |
| 5761- | CAPE, | Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of AMPK and Akt signaling networks |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 5882- | CAR, | Carvacrol Promotes Cell Cycle Arrest and Apoptosis through PI3K/AKT Signaling Pathway in MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 |
| 5888- | CAR, | Therapeutic application of carvacrol: A comprehensive review |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Diabetic, | NA | - | Review, | Park, | NA |
| 5891- | CAR, | SRF, | Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7 |
| - | in-vivo, | HCC, | NA |
| 5939- | Cela, | Chemo, | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | Melanoma, | RPMI-8226 |
| 5944- | Cela, | HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way |
| - | in-vitro, | AML, | U937 |
| 6615- | Cen, | Asiaticoside suppresses cell proliferation by inhibiting the NF-κB signaling pathway in colorectal cancer |
| - | vitro+vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | LoVo |
| 6640- | Cen, | Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | QGY-7703 |
| 6652- | Cen, | AA-PMe, a novel asiatic acid derivative, induces apoptosis and suppresses proliferation, migration, and invasion of gastric cancer cells |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | HGC27 |
| 6002- | CGA, | Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 6067- | CHL, | Antiproliferative effect of chlorophyllin derived from a traditional Chinese medicine Bombyx mori excreta on human breast cancer MCF-7 cells |
| - | in-vitro, | BC, | MCF7 |
| 6132- | CHr, | MET, | Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression |
| - | in-vitro, | BC, | T47D |
| 2782- | CHr, | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2784- | CHr, | Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review) |
| - | Review, | Var, | NA |
| 2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
| - | Review, | Var, | NA |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2790- | CHr, | Chrysin: Pharmacological and therapeutic properties |
| - | Review, | Var, | NA |
| 1145- | CHr, | Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways |
| - | in-vitro, | Cerv, | HeLa |
| 6294- | Cro, | Crocetin and Crocin from Saffron in Cancer Chemotherapy and Chemoprevention |
| - | Review, | Var, | NA |
| 6195- | Cuc, | Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends |
| - | Review, | Var, | NA |
| 6201- | Cuc, | Cucurbitacin B and Its Derivatives: A Review of Progress in Biological Activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6214- | CUR, | Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve |
| 6720- | CUR, | SFN, | DHCA, | Synergistic Combinations of Curcumin, Sulforaphane, and Dihydrocaffeic Acid against Human Colon Cancer Cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Nor, | FHC |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4709- | CUR, | Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways |
| - | Review, | Var, | NA |
| 470- | CUR, | Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line |
| - | in-vitro, | Ovarian, | SKOV3 |
| 437- | CUR, | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids |
| - | vitro+vivo, | CRC, | TCO1 | - | vitro+vivo, | CRC, | TCO2 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 126- | CUR, | Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| - | Review, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:73 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid